Global Cord Blood (CO) Stock Analysis

What Global Cord Blood does

Global Cord Blood Corporation (GCBC), alongside its associated entities, provides specialized services related to umbilical cord blood within the People's Republic of China. The company's operations involve the testing, processing, and long-term storage of cord blood for both private subscribers and donated samples. For the latter, it also facilitates donor matching. As of March 31, 2022, GCBC managed three cord blood banks situated in key regions: Beijing municipality, Guangdong province, and Zhejiang province. The company, which is headquartered in Central, Hong Kong, rebranded as Global Cord Blood Corporation in March 2018, having previously been known as China Cord Blood Corporation. Currently, it functions as a subsidiary under Blue Ocean Structure Investment Company Ltd.

Key metrics

ETFs linked to CO

Broad-market and Healthcare sector ETFs an investor holding Global Cord Blood is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Global Cord Blood?

Global Cord Blood trades under the ticker CO on NYSE.

Which exchange is CO listed on?

CO is listed on NYSE.

What sector does Global Cord Blood operate in?

Global Cord Blood is classified in the Healthcare sector (Medical - Diagnostics & Research industry).

How can PortView help analyze CO in a portfolio?

PortView shows CO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.